Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, With an Active Control Vaccine, Phase I Clinical Trial for Evaluation of Safety and Immunogenicity of a Recombinant Inactivated COVID-19 Vaccine in Adults in Brazil - ADAPTCOV

NCT04993209 is registered in ClinicalTrials.gov with Butantan Institute as lead sponsor.

NCT NCT04993209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04993209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, With an Active Control Vaccine, Phase I Clinical Trial for Evaluation of Safety and Immunogenicity of a Recombinant Inactivated COVID-19 Vaccine in Adults in Brazil - ADAPTCOV
Lead sponsor
Butantan Institute
Phase
Phase 1
Overall status
Completed
Start date
July 9, 2021
Completion date
November 4, 2022
Enrollment
320 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus infections, healthy